Clinical outcomes of bacteremic pneumococcal pneumonia in the era of antibiotic resistance

J. F. Moroney, A. E. Fiore, L. H. Harrison, Jan E Patterson, M. M. Farley, J. H. Jorgensen, M. Phelan, R. R. Facklam, M. S. Cetron, R. F. Breiman, M. Kolczak, A. Schuchat

Research output: Contribution to journalArticle

117 Citations (Scopus)

Abstract

Limited data are available about the impact of antimicrobial resistance on clinical outcomes in cases of pneumococcal pneumonia. This was studied in 146 persons hospitalized with invasive pneumonia due to Streptococcus pneumoniae (minimum inhibitory concentration of cefotaxime, ≥.25 μg/mL) who were identified through population-based active surveillance for the period of November 1994 through April 1996. Compared with matched control subjects who had infection with more-susceptible S. pneumoniae, the proportion of subjects who died or who were admitted to an intensive care unit did not differ significantly. Multivariable analysis showed no significant contribution of antimicrobial resistance to mortality or the requirement for care in an intensive care unit. The ability to detect an effect of antimicrobial resistance on these important outcome measures may have been influenced by aggressive multidrug empirical therapy in this group of hospitalized patients. Factors other than resistance, such as severity of illness at presentation and advance directive status ("do not resuscitate" orders), appear to have a stronger influence on pneumococcal pneumonia outcomes.

Original languageEnglish (US)
Pages (from-to)797-805
Number of pages9
JournalClinical Infectious Diseases
Volume33
Issue number6
DOIs
StatePublished - Sep 15 2001

Fingerprint

Pneumococcal Pneumonia
Microbial Drug Resistance
Streptococcus pneumoniae
Intensive Care Units
Resuscitation Orders
Advance Directives
Aptitude
Cefotaxime
R Factors
Microbial Sensitivity Tests
Group Psychotherapy
Pneumonia
Outcome Assessment (Health Care)
Mortality
Infection
Population

ASJC Scopus subject areas

  • Immunology

Cite this

Moroney, J. F., Fiore, A. E., Harrison, L. H., Patterson, J. E., Farley, M. M., Jorgensen, J. H., ... Schuchat, A. (2001). Clinical outcomes of bacteremic pneumococcal pneumonia in the era of antibiotic resistance. Clinical Infectious Diseases, 33(6), 797-805. https://doi.org/10.1086/322623

Clinical outcomes of bacteremic pneumococcal pneumonia in the era of antibiotic resistance. / Moroney, J. F.; Fiore, A. E.; Harrison, L. H.; Patterson, Jan E; Farley, M. M.; Jorgensen, J. H.; Phelan, M.; Facklam, R. R.; Cetron, M. S.; Breiman, R. F.; Kolczak, M.; Schuchat, A.

In: Clinical Infectious Diseases, Vol. 33, No. 6, 15.09.2001, p. 797-805.

Research output: Contribution to journalArticle

Moroney, JF, Fiore, AE, Harrison, LH, Patterson, JE, Farley, MM, Jorgensen, JH, Phelan, M, Facklam, RR, Cetron, MS, Breiman, RF, Kolczak, M & Schuchat, A 2001, 'Clinical outcomes of bacteremic pneumococcal pneumonia in the era of antibiotic resistance', Clinical Infectious Diseases, vol. 33, no. 6, pp. 797-805. https://doi.org/10.1086/322623
Moroney, J. F. ; Fiore, A. E. ; Harrison, L. H. ; Patterson, Jan E ; Farley, M. M. ; Jorgensen, J. H. ; Phelan, M. ; Facklam, R. R. ; Cetron, M. S. ; Breiman, R. F. ; Kolczak, M. ; Schuchat, A. / Clinical outcomes of bacteremic pneumococcal pneumonia in the era of antibiotic resistance. In: Clinical Infectious Diseases. 2001 ; Vol. 33, No. 6. pp. 797-805.
@article{9f55ba25e54a49efbe447aceb00cf3f0,
title = "Clinical outcomes of bacteremic pneumococcal pneumonia in the era of antibiotic resistance",
abstract = "Limited data are available about the impact of antimicrobial resistance on clinical outcomes in cases of pneumococcal pneumonia. This was studied in 146 persons hospitalized with invasive pneumonia due to Streptococcus pneumoniae (minimum inhibitory concentration of cefotaxime, ≥.25 μg/mL) who were identified through population-based active surveillance for the period of November 1994 through April 1996. Compared with matched control subjects who had infection with more-susceptible S. pneumoniae, the proportion of subjects who died or who were admitted to an intensive care unit did not differ significantly. Multivariable analysis showed no significant contribution of antimicrobial resistance to mortality or the requirement for care in an intensive care unit. The ability to detect an effect of antimicrobial resistance on these important outcome measures may have been influenced by aggressive multidrug empirical therapy in this group of hospitalized patients. Factors other than resistance, such as severity of illness at presentation and advance directive status ({"}do not resuscitate{"} orders), appear to have a stronger influence on pneumococcal pneumonia outcomes.",
author = "Moroney, {J. F.} and Fiore, {A. E.} and Harrison, {L. H.} and Patterson, {Jan E} and Farley, {M. M.} and Jorgensen, {J. H.} and M. Phelan and Facklam, {R. R.} and Cetron, {M. S.} and Breiman, {R. F.} and M. Kolczak and A. Schuchat",
year = "2001",
month = "9",
day = "15",
doi = "10.1086/322623",
language = "English (US)",
volume = "33",
pages = "797--805",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - Clinical outcomes of bacteremic pneumococcal pneumonia in the era of antibiotic resistance

AU - Moroney, J. F.

AU - Fiore, A. E.

AU - Harrison, L. H.

AU - Patterson, Jan E

AU - Farley, M. M.

AU - Jorgensen, J. H.

AU - Phelan, M.

AU - Facklam, R. R.

AU - Cetron, M. S.

AU - Breiman, R. F.

AU - Kolczak, M.

AU - Schuchat, A.

PY - 2001/9/15

Y1 - 2001/9/15

N2 - Limited data are available about the impact of antimicrobial resistance on clinical outcomes in cases of pneumococcal pneumonia. This was studied in 146 persons hospitalized with invasive pneumonia due to Streptococcus pneumoniae (minimum inhibitory concentration of cefotaxime, ≥.25 μg/mL) who were identified through population-based active surveillance for the period of November 1994 through April 1996. Compared with matched control subjects who had infection with more-susceptible S. pneumoniae, the proportion of subjects who died or who were admitted to an intensive care unit did not differ significantly. Multivariable analysis showed no significant contribution of antimicrobial resistance to mortality or the requirement for care in an intensive care unit. The ability to detect an effect of antimicrobial resistance on these important outcome measures may have been influenced by aggressive multidrug empirical therapy in this group of hospitalized patients. Factors other than resistance, such as severity of illness at presentation and advance directive status ("do not resuscitate" orders), appear to have a stronger influence on pneumococcal pneumonia outcomes.

AB - Limited data are available about the impact of antimicrobial resistance on clinical outcomes in cases of pneumococcal pneumonia. This was studied in 146 persons hospitalized with invasive pneumonia due to Streptococcus pneumoniae (minimum inhibitory concentration of cefotaxime, ≥.25 μg/mL) who were identified through population-based active surveillance for the period of November 1994 through April 1996. Compared with matched control subjects who had infection with more-susceptible S. pneumoniae, the proportion of subjects who died or who were admitted to an intensive care unit did not differ significantly. Multivariable analysis showed no significant contribution of antimicrobial resistance to mortality or the requirement for care in an intensive care unit. The ability to detect an effect of antimicrobial resistance on these important outcome measures may have been influenced by aggressive multidrug empirical therapy in this group of hospitalized patients. Factors other than resistance, such as severity of illness at presentation and advance directive status ("do not resuscitate" orders), appear to have a stronger influence on pneumococcal pneumonia outcomes.

UR - http://www.scopus.com/inward/record.url?scp=17944367298&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17944367298&partnerID=8YFLogxK

U2 - 10.1086/322623

DO - 10.1086/322623

M3 - Article

C2 - 11512085

AN - SCOPUS:17944367298

VL - 33

SP - 797

EP - 805

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 6

ER -